Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,307 matching trials from the live ClinicalTrials.gov search.
Conditions
Obesity or Overweight
Interventions
Placebo, Enicepatide
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more
Completed Phase 2 Interventional Results available

Losartan to Reverse Sickle Nephropathy

NCT01479439
Conditions
Nephropathy, Sickle Cell Anemia
Interventions
Losartan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Chicago, Illinois • Louisville, Kentucky • Bethesda, Maryland + 5 more
Conditions
Asthma
Interventions
albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA), HFA placebo
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Mobile, Alabama • Huntington Beach, California • Long Beach, California + 34 more
Active, not recruiting No phase listed Observational

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04387656
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 19 more
Suspended No phase listed Observational

Tapestry Rotator Cuff Repair PMCF

NCT06287853
Conditions
Rotator Cuff Tears, Rotator Cuff Injuries
Interventions
Tapestry Biointegrative Implant
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Pomona, California • Louisville, Kentucky • Baltimore, Maryland
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Completed No phase listed Observational Accepts healthy volunteers

Ovarian Screening Study

NCT00267072
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
25 Years and older · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Terminated Phase 1Phase 2 Interventional Results available

A Study of ONO-7475 in Patients With Acute Leukemias

NCT03176277
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily, ONO-7475 6mg + Venetoclax (70-400mg)
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Los Angeles, California • North Haven, Connecticut • Gainesville, Florida + 12 more
Conditions
Malignant Glioma
Interventions
Irinotecan (Camptosar, CPT-11)
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Liver Lymphoma, Mantle Cell Lymphoma
Interventions
Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
504
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 358 more
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Conditions
Heart Failure, Congestive
Interventions
DITPA (3,5-diiodothyropropionic acid), Placebo
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Huntsville, Alabama • Peoria, Arizona • Tucson, Arizona + 18 more
Conditions
Suicide and Self-harm
Interventions
CAMS-G
Behavioral
Lead sponsor
Louisville VA Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
B-cell Non Hodgkin Lymphoma
Interventions
ARC-02, Rituximab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Los Angeles, California • Louisville, Kentucky • New York, New York + 4 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
Conditions
Neuroblastoma
Interventions
filgrastim, sargramostim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2011
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
Non Hodgkin Lymphoma
Interventions
acalabrutinib, rituximab (IV), Lenalidomide
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Downey, California • Duarte, California + 18 more
Conditions
Spinal Deformity
Interventions
Not listed
Lead sponsor
Shay Bess
Other
Eligibility
40 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Sacramento, California • San Francisco, California • Denver, Colorado + 6 more
Conditions
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Completed No phase listed Observational Results available

ClotTriever Outcomes (CLOUT) Registry

NCT03575364
Conditions
Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
Interventions
ClotTriever
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 37 more
Conditions
Herpes Simplex
Interventions
Valaciclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more